© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Nov 28, 2015, the consensus forecast amongst 20 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 16 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 130.00, with a high estimate of 138.00 and a low estimate of 102.00. The median estimate represents a 22.82% increase from the last price of 105.85. View Full Financials
Historical dividend information is not available for Gilead Sciences Inc. View Full Financials
|Div growth (TTM)||--|
On Oct 27, 2015, Gilead Sciences, Inc. reported 3rd quarter 2015 earnings of 3.22 per share. This result exceeded the 2.88 consensus of the 17 analysts covering the company and exceeded last year's 3rd quarter results by 57.07%.
The next earnings announcement is expected on Feb 01, 2016. View Full Interim Financials
|Average growth rate||+12.22 %|
Gilead Sciences, Inc. reported annual 2014 earnings of 8.09 per share on Feb 03, 2015.
The next earnings announcement from Gilead Sciences, Inc. is expected the week of Feb 01, 2016. View Full Annual Financials
|Average growth rate||+76.71 %|
Gilead Sciences Inc. had 3rd quarter 2015 revenues of 8.30bn. This bettered the 7.85bn consensus of the 15 analysts covering the company. This was 37.29% above the prior year's 3rd quarter results. View Full Interim Financials
|Average growth rate||+8.52 %|
Gilead Sciences Inc. had revenues for the full year 2014 of 24.89bn. This was 122.20% above the prior year's results. View Full Annual Financials
|Average growth rate||+39.71 %|